Parexcel is the CRO

[biopearl123]

http://ir.geron.com/node/15861/html

[huntingonthebluffs]

#4 of top ten CROs in 2018.

https://www.igeahub.com/2018/03/15/top- ... -2018/amp/

[karagozoglu12345]

Compensation levels seem to be high for a stock that has been trading near its cash value. I understand that getting talent on board is a costly endevour. But, I would think there has to be some way to tie compensation to results. I wonder what was the rationale for Dr. Scarlett's bonus ( 280,000$) in 2018 which was a disasterous year for the investors?

[nerdyboy99]

'C' level compensation has absolutely no tie to how shareholders fared. Bonuses are negotiated and offered as part of an overall compensation package.

I, for one, read the post-continuation documents and ASH follow ups and I am very happy with the way this shipped is being righted. I feel the compensation is adaquet in this very competative landscape. Scarlet is doing a good job. 2019 will be a big year.

"Disastrous"?
I have a substantial position and I haven't lost a cent. I am confident on the future of Geron. What disaster?

[karagozoglu12345]

What disaster? If your cost basis was near cash value then you wouldn't loose a cent on paper. There are many of us who had been mislead by Janssen before CD with cost basis over 5$. Yes, so far it has been a disaster for me. I hope tide will turn this year.
I agree that bonuses are most likely negotiated as part of the overall compensation package. Salaries are generally stable irrespective of a company's performance. Should bonus not be a function of performance as well? By definition bonus serves as a reward for good performance.